NCT06849518View on ClinicalTrials.gov

Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer

NARecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions

Lung Cancer (NSCLC)

Interventions

DIAGNOSTIC_TEST

Circulogene liquid biopsy testing

A Circulogene liquid biopsy testing for plasma NGS ctDNA and plasma cfRNA PD-L1 expression.

Trial Locations (1)

37660

RECRUITING

Ballad Health Cancer Care, Kingsport

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Ballad Health

OTHER

NCT06849518 - Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer | Biotech Hunter | Biotech Hunter